Melanoma cells release small extracellular packages containing the protein nerve growth factor receptor, which primes nearby lymph nodes for tumor metastases, according to a new study by Weill Cornell Medicine investigators.
A new protein variant underlies the ability of gastric cancers to resist an otherwise effective family of chemotherapy drugs, according to a study by a multidisciplinary team at Weill Cornell Medicine. The results suggest a treatment strategy that could improve the prognoses of many patients with cancer.
Treatment with arginine, one of the amino-acid building blocks of proteins, enhanced the effectiveness of radiation therapy in cancer patients with brain metastases, in a proof-of-concept, randomized clinical trial from investigators at Weill Cornell Medicine and Angel H. Roffo Cancer Institute.
Lymphomas can turbo-charge their ability to proliferate by crowding growth-supporting enzymes into highly concentrated compartments within tumor cells, according to a study led by researchers at Weill Cornell Medicine.
A team led by researchers at Weill Cornell Medicine, the New York Genome Center, Harvard Medical School, Massachusetts General Hospital and the Broad Institute of MIT and Harvard has profiled in unprecedented detail thousands of individual cells sampled from patients’ brain tumors.
Turning off a defense mechanism that protects colorectal cancer tumors from being discovered by immune cells could be a possible strategy for treating the disease.
A team co-led by scientists at Weill Cornell Medicine has revealed in detail how the most common primary eye cancer in adults, uveal melanoma (UM), can progress from a slow-growing, “indolent” state to a lethal metastasizing state. The discovery is a significant advance in fundamental cancer research that also suggests new strategies for treatment.
Treatment with a ready-made preparation of human immune cells helps prevent infections in people whose immune systems are temporarily weakened by leukemia treatment.
A new understanding of the interaction of two proteins and their role in fat burning and storage may one day have implications for the treatment of obesity and associated diseases such as diabetes and cancer, according to Weill Cornell Medicine investigators.
Scientists have made major advances in understanding and developing treatments for many cancers by identifying genetic mutations that drive the disease. Now a team led by researchers at Weill Cornell Medicine, NewYork-Presbyterian and the New York Genome Center (NYGC) has developed a machine learning technique for detecting other modifications to DNA that have a similar effect.
Weill Cornell Medicine has received complementary grants from Genentech and the Leukemia & Lymphoma Society (LLS) to support a new program that aims to address socioeconomic and racial disparities and increase access to clinical trials for underserved patients with blood cancers living in Brooklyn and Queens.
Weill Cornell Medicine physician-scientist Dr. David Lyden, whose research has led to groundbreaking discoveries about how cancer spreads, has been elected into the esteemed Association of American Physicians.
Molecular "bookmarks," which allow cells to retain their characteristics during cell division, ensure fast reactivation of critical cell identity genes after cell division, according to investigators at Weill Cornell Medicine.
Cancer cells can dodge chemotherapy by entering a state that bears similarity to certain kinds of senescence, a type of “active hibernation” that enables them to weather the stress induced by aggressive treatments aimed at destroying them, according to a new study by scientists at Weill Cornell Medicine. These findings have implications for developing new drug combinations that could block senescence and make chemotherapy more effective.
Cancer biologists at Weill Cornell Medicine have been awarded a 2021 Top 10 Clinical Research Achievement Award from the Clinical Research Forum for their study last year describing a highly sensitive blood test for monitoring cancer progression and relapse.
The environment surrounding the cancerous cells of a lymphoma tumor has a strong influence on the progression of these blood-cell cancers and their responses to therapies.
Much of the three-dimensional architecture of the genome in antibody-producing immune cells is dependent on a gene called SMC3. When this gene is not working properly it can lead to improper immune cell development and to cancer, by disrupting how DNA is structured inside the cell nucleus, according to a team of researchers from Weill Cornell Medicine.
Researchers at Weill Cornell Medicine have gleaned new insights on the ways cells maintain the tips of their chromosomes, or telomeres. The findings help illuminate a wide range of phenomena, from cancer development to fungal evolution.
Mutations in proteins called histone H1, which help package DNA in chromosomes, are a frequent cause of lymphomas, according to a study led by researchers at Weill Cornell Medicine, NewYork-Presbyterian and The Rockefeller University. The findings could lead to new approaches to treating these cancers.
